CD8A and cancer: Despite the emergence of therapeutic monoclonal antibodies targeting immune checkpoints, a lack of response to malignant tumors has been observed.[19] To overcome immune resistance, it is necessary to transform an immunologically unresponsive “cold” tumor into a “hot” tumor (Figure 8a).[43] “Cold” tumors are characterized by, 1) low antigen loadings, 2) low T cell infiltration, and 3) high expression of immune‐suppressive factors.[44] ICD by AIMS(PTX) successfully generated tumor‐associated antigens, and supra‐adjuvant therapy increased CD8+ T cell counts in the TME.